Brought to you by 
Intrexon pulls in $95.2mm through FOPO
26 Jan 2015
Executive Summary
Life sciences company Intrexon Corp. (synthetic biology) netted $95.2mm in a follow-on offering of 3.75mm shares at $27. The company earlier this month licensed, along with partner Ziopharm Oncology, the University of Texas MD Anderson Cancer Center’s technologies relating to CAR T-cells, which it will use with its own DNA platforms to develop and commercialize nonviral adoptive cellular therapies for cancer.
Deal Industry
- Diversified
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com